Child and Adolescent Psychiatric Clinics of North America
Volume 15, Issue 1 , Pages 13-50, January 2006

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Update on New Stimulant Preparations, Atomoxetine, and Novel Treatments

  • Jefferson B. Prince, MD

      Affiliations

    • Department of Child Psychiatry, Massachusetts General Hospital, Harvard Medical School, 6900 Yawkey Building, 15 Parkman Street, Boston, MA 02114, USA
    • Child and Adolescent Psychiatry, North Shore Medical Center, 57 Highland Avenue, Salem, MA 01970, USA
    • Corresponding Author InformationDepartment of Child Psychiatry, Massachusetts General Hospital, Harvard Medical School, 6900 Yawkey Building, 15 Parkman Street, Boston, MA 02114

This article reviews data on the safety, tolerability, and efficacy of the extended-delivery stimulant preparations and atomoxetine, including nine methylphenidate formulations, five amphetamine formulations, and one norepinephrine reuptake inhibitor, now indicated for treatment of attention-deficit hyperactivity disorder (ADHD). Six of the nine methylphenidate formulations, three of the five compounds, and the norepinephrine reuptake inhibitor are long-acting, potentially once-daily agents. Data on treatment of common adverse events are described, and data on investigational treatments of ADHD are reviewed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Prince has received research funding, honoraria, consulting fees, and speaker bureau funding from McNeil, Lilly, Forest, Novartis, Shire, GlaxoSmithKline, Astra-Zeneca, and Pfizer Pharmaceuticals.

PII: S1056-4993(05)00067-2

doi:10.1016/j.chc.2005.08.002

Child and Adolescent Psychiatric Clinics of North America
Volume 15, Issue 1 , Pages 13-50, January 2006

Article Tools